Latest From AM-Pharma BV
Century Therapeutics brings in $250m for its cell therapy programs in a series A round, while immunotherapy specialist BioNTech sets a record for series B, raising $350m. Another five firms brought in rounds of $100m or greater...
Private Company Edition: IPOs and M&A are returning money to investors, who are putting that money into new investments. Also, the mega-push in VC mega-rounds continues, including $105m for Kronos, and RA Capital raises it first VC fund.
Following Pfizer’s decision not to take up an option to acquire the Dutch company, AM-Pharma has returned to the venture capital market to get backing for a single pivotal Phase III trial of reCAP in acute kidney injury.
Ghent, Belgium-based start-up, AgomAb Therapeutics NV secures funds and license to develop HGF-mimetic agonistic monoclonal antibodies for regeneration of damaged tissues.
- Large Molecule
- Therapeutic Areas
- Renal System
- AM-Pharma Holdings BV
- Western Europe
- Parent & Subsidiaries
- AM-Pharma BV
- Senior Management
Erik van den Berg, CEO
Peter Verwayen, VP, Fin.
Jacques Arend, MD, VP, Clin. Dev. & CMO
Tim Knotnerus, Sr. Dir., Bus. Dev.
- Contact Info
Phone: (31) 30 228 9222
, 3981 AK
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.